Survival benefits of Cytoreductive Nephrectomy in patients with metastatic renal cell carcinoma: evidence from a SEER-based retrospective cohort study.

ABSTRACT:

Background

Metastatic renal cell carcinoma (mRCC) is associated with poor prognosis, with a 5-year survival rate of less than 15%. Cytoreductive nephrectomy (CN) has historically played a critical role in mRCC management, potentially enhancing systemic therapy efficacy by reducing tumor burden. However, its relevance in the era of targeted therapies and immune checkpoint inhibitors (ICIs) has been questioned.

Objective

This study evaluates the survival benefits of CN in mRCC patients using real-world, population-based data from the SEER database.

Methods

A retrospective cohort analysis of 6,030 mRCC patients was performed using data from 2010 to 2017. Propensity score matching (PSM) minimized selection bias, yielding 1,350 matched patients. Kaplan-Meier survival curve

SUBMITTER: Peng X 

PROVIDER: S-EPMC12262855 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature